Last reviewed · How we verify
MK0217, /Duration of Treatment : 12 Months
MK0217, /Duration of Treatment : 12 Months is a Small molecule drug developed by Organon and Co. It is currently in Phase 3 development.
MK0217 is an investigational compound developed by Organon that modulates a specific molecular target to treat its indicated condition.
At a glance
| Generic name | MK0217, /Duration of Treatment : 12 Months |
|---|---|
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without publicly available detailed mechanism information for MK0217, the exact molecular target and pathway remain unclear from standard pharmaceutical databases. The drug is in Phase 3 development with a 12-month treatment duration, suggesting a chronic condition indication. Further clinical trial data would be needed to characterize its precise mechanism of action.
Approved indications
Common side effects
Key clinical trials
- A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED) (PHASE3)
- A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK0217, /Duration of Treatment : 12 Months CI brief — competitive landscape report
- MK0217, /Duration of Treatment : 12 Months updates RSS · CI watch RSS
- Organon and Co portfolio CI